<qa>  What is the aim of this pilot study?The aim of this pilot study is to correlate the sorafenib plasma concentration to observed toxicity and to the disease control rate in 100 patients undergoing a palliative treatment of hepatocellular carcinoma HCC. If some correlations are observed, we will consider planning a larger interventional study to adjust sorafenib daily dose to plasma concentration. 